Amy has been a drug discovery and development professional for 25+ years, including progressive roles in clinical operations and clinical strategy. Her clinical development experience spans all therapeutic areas and all stages of the clinical development lifecycle, from natural history studies through registrational global trials, and Long-Term Follow Up and Post Marketing surveillances.
In addition to her grasp of the unique dynamics of developing novel treatments for rare and complex diseases, Amy also leverages her combination of training and experience leading the Cell and Gene Therapy Hub at Worldwide Clinical Trials. This experience includes gene therapy, cell therapy, gene-modified cell therapy, and gene editing treatments for oncology and rare disease patient communities. Her experiences in academia, biotech, and CROs confirm that meeting the needs of all stakeholders – payers, regulators, patients, families, and sites – is a critical success factor for efficient development programs.